

## Lecture su invito Sessioni Plenarie SIBioC-SIMeL

<b>Renal failure</b>	
V. Sepe .....	103
<b>Standardization of the measurements of creatinine and new markers of renal insufficiency: an update</b>	
F. Ceriotti .....	104
<b>Glomerular filtration rate measurement: from equations to report consensus</b>	
D. Giavarina .....	105
<b>Urinary Albumin Excretion in chronic kidney disease: critical issues in measurement and reporting</b>	
M.S. Graziani .....	106
<b>Biomarkers: state of the art and perspectives</b>	
G. Castaldo .....	107
<b>Can we personalize drug therapy in colorectal cancer patients?</b>	
F. Innocenti .....	108
<b>High Sensitivity C-reactive protein and other markers of cardiovascular inflammation: from bench to prove of efficacy</b>	
L.M. Biasucci .....	109
<b>Non invasive diagnosis of gastrointestinal disorders: GastroPanel and Fibrotest</b>	
D. Basso .....	110
<b>Clinical risk: from problem to opportunity</b>	
S. Dente .....	111
<b>FMEA-FMECA: a risk management's strument for critical processes</b>	
R. Locont .....	112
<b>Pre-analytical phase: Risk Management and Risk Assessment in a Hospital Laboratory</b>	
S. Galmarini, G. Catanoso, G. Casiraghi .....	113
<b>Risk management triggers in postanalytical phase</b>	
M. Morandini .....	114
<b>Pharmacogenetics: promise or reality?</b>	
R.H.N. van Schaik .....	115
<b>Pharmacogenetics and clinical oncology: a new deal for personalized therapies</b>	
S. Martinotti, S. Ursi, B. De Laurentiis, S. Matera, G. Vitullo, A. Allegrini, A. Tessitore, V. Flati, E. Toniato .....	116
<b>Pharmacogenetics and diabetes</b>	
R. Testa, F. Olivieri .....	118
<b>Pharmacogenetics of oral anticoagulant therapy</b>	
G. Lippi .....	119